INSEAD Alumni group meeting for healthcare professionals

1. Risk Management and Innovation in the Health Care Industry:
Are they (in)compatible?
Introduction
Dr. David Cocker
The ‘Big Pharma’ point of view
Dr. Gerd Johnscher
Senior Partner, MDCPartners
Senior Consultant, Pharmakon
Former Senior VP, Adviser to the CEO, UCB
The ‘Regulator’s point of view
Prof. Bruno Flamion
FUNDP – University of Namur and CHMP
The ‘Economist’s and Innovator’ point of view
Prof. Koenraad Debackere
Managing Director of K. U. Leuven R&D
Chairman of Gemma Frisius-Fonds
The ‘End-user’s’ point of view
Mr. Jo De Cock
General Manager, RIZIV/INAMI

2. Risk Management and Innovation in the
healthcare industry
are they (in)compatible ?
Good evening,
my name is David Cocker and I am in the chair tonight.

3. Talking about risk is of course one of
the riskiest things one can do.
There are so many experts about !
( J.D.Remington, HSE, UK )

4. What’s risk ?
its very simple
• The risk the first speaker will look up
• wikipedia.org/historical_background/ “the definition of risk”.

5. Once risks was in the
hands of
“others”
Thx Peter Bernstein & Rembrandt

6. Most of us view risk as either ……acceptable
…………..or unacceptable
That’s if we have a choice …………..

7. Reputational
• People
• Share price
Environmental
• Ecotox
• Compliance
Risk
Financial
• Investments
• Liabilities
Human Health
• Efficacy
• Safety

8. Risk Management
Mitigate the risk of injury
Mitigate the risk of accidents

9. Study suggests heart attack risk
persisted for one year after
patients stopped taking Vioxx.
Oct. 14 issue of The Lancet. The study "also
appears to show the higher risk started soon
after patients began taking Vioxx, though" the
analysis "notes a small sample size precludes
a definitive finding on this issue."

10. Do you hold a good hand of cards ?

11. NGO’s are good at communicating
emotion
The industry is good at
communicating data.

12. Risk communication will be as important as
the data to substantiate it

13. time
RISK MANAGEMENT
RISK ASSESSMENT
 Hazard identification
 Dose (conc)-response (effect)
 Exposure assessment
RISK CHARACTERIZATION
DECISIONS & ACTIONS
You need a plan
Management option:
Consequences of the options at
public health, economic, social &
political levels

14. Towards an Evidence-based
Toxicology
Expert-based
vs.
toxicology
evidence-based

15. Design Strategies
Reducing Environmental
Footprint
•
Reformulate the product
X2
•
Redesign the product
X5
•
New ways to deliver function
X 10
•
Redesign the system
X 20
Source : Miller, Chemistry Innovation (2007)